Wire · regulatory
Dr. Reddy's Laboratories Receives US FDA Approval For Rituximab Biosimilar
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 August 2026 · Fusion42 review
Dr. Reddy's Laboratories has received U.S. FDA approval for its rituximab biosimilar, enabling commercialisation in the United States through partner Fresenius Kabi. This regulatory milestone positions the company for a significant medium-to-long term revenue opportunity in the competitive U.S. biosimilars market.
This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.
◆ ◆ The Wire takeaway
Your biotech firm must adjust to tougher US biologics competition now that Dr. Reddy's has entered with an FDA-approved biosimilar. Watch Fresenius Kabi's US launch closely as it shapes market access and pricing you will face this year.
◆ Related on Wire
◆ Topics